Androgen‐modulating agents for spinal bulbar muscular atrophy/Kennedy's disease
References
Additional references
Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005;128(Pt 3):659‐70. [PUBMED: 15659427]
Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006;129(Pt 6):1446‐55. [PUBMED: 16621916]
Banno H, Katsuno M, Suzuki K, Tanaka F, Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA). Cell and Tissue Research 2012;349(1):313‐20. [PUBMED: 22476656]
Chevalier‐Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. Journal of Neuroscience 2004;24(20):4778‐86. [PUBMED: 15152038]
Dejager S, Bry‐Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. Journal of Clinical Endocrinology and Metabolism 2002;87(8):3893‐901. [PUBMED: 12161529]
Fernandez‐Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo‐controlled trial. Lancet Neurology 2011;10(2):140‐7.
Finsterer J. Perspectives of Kennedy's disease. Journal of the Neurological Sciences 2010;298(1‐2):1‐10. [PUBMED: 20846673]
Guidetti D, Sabadini R, Ferlini A, Torrente I. Epidemiological survey of X‐linked bulbar and spinal muscular atrophy, or Kennedy disease, in the province of Reggio Emilia, Italy. European Journal of Epidemiology 2001;17(6):587‐91. [PUBMED: 11949733]
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32‐8. [PUBMED: 12667885]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jenkinson C, Fitzpatrick R. Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ‐5. Journal of Neurology, Neurosurgery & Psychiatry 2001;70(1):70‐3.
Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002;35(5):843‐54. [PUBMED: 12372280]
Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, et al. Leuprorelin rescues polyglutamine‐dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Medicine 2003;9(6):768‐73. [PUBMED: 12754502]
Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Experimental Neurology 2006;200(1):8‐18. [PUBMED: 16513111]
Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010;9(9):875‐84. [PUBMED: 20691641]
Katsuno M, Banno H, Suzuki K, Adachi H, Tanaka F, Sobue G. Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA). Advances in Experimental Medicine and Biology 2010;685:64‐74. [PUBMED: 20687495]
Katsuno M, Tanaka F, Adachi H, Banno H, Suzuki K, Watanabe H, et al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Progress in Neurobiology 2012;99(3):246‐56. [PUBMED: 22609045]
Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex‐linked recessive trait. Neurology 1968;18(7):671‐80. [PUBMED: 4233749]
La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X‐linked spinal and bulbar muscular atrophy. Nature 1991;352(6330):77‐9. [PUBMED: 2062380]
La Spada AR. Spinal and Bulbar Muscular Atrophy. In: Pagon RA, Adam MP, Ardinger HH, et al. editor(s). GeneReviews ® [Internet]. University of Washington, Seattle, 1999 Feb 26 (Updated 2014 Jul 3). [Available from: http://www.ncbi.nlm.nih.gov/books/NBK1333/]
Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Annals of Neurology 1998;44(2):249‐54. [PUBMED: 9708548]
Parodi S, Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Frontiers in Neuroendocrinology 2011;32(4):416‐25. [PUBMED: 21745497]
Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Frontiers in Neuroendocrinology 2004;25(1):1‐26. [PUBMED: 15183036]
Pozzi P, Bendotti C, Simeoni S, Piccioni F, Guerini V, Marron TU, et al. Androgen 5‐alpha‐reductase type 2 is highly expressed and active in rat spinal cord motor neurones. Journal of Neuroendocrinology 2003;15(9):882‐7. [PUBMED: 12899683]
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine 2009;6(6):e1000097. [DOI: 10.1371/journal.pmed1007]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, et al. Clinical features of spinal and bulbar muscular atrophy. Brain 2009;132(Pt 12):3242‐51. [PUBMED: 19846582]
Roehrborn CG, Siami P, Barkin J, Damiao R, Major‐Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2‐year results from the CombAT study. The Journal of Urology 2008;179(2):616‐21; discussion 621. [PUBMED: 18082216]
Sar M, Stumpf WE. Androgen concentration in motor neurons of cranial nerves and spinal cord. Science (New York, N.Y.) 1977;197(4298):77‐9. [PUBMED: 867053]
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, et al. Androgen‐dependent neurodegeneration by polyglutamine‐expanded human androgen receptor in Drosophila. Neuron 2002;35(5):855‐64. [PUBMED: 12372281]
Tanaka F, Doyu M, Ito Y, Matsumoto M, Mitsuma T, Abe K, et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Human Molecular Genetics 1996;5(9):1253‐7. [PUBMED: 8872464]
Tanaka F, Katsuno M, Banno H, Suzuki K, Adachi H, Sobue G. Current status of treatment of spinal and bulbar muscular atrophy. Neural Plasticity 2012:369284. [DOI: 10.1155/2012/369284; PUBMED: 22720173]
Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha‐reductase isozyme expression. Journal of Clinical Investigation 1993;92(2):903‐10. [PUBMED: 7688765]
Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha‐reductase isoenzymes in the prevention and treatment of prostate cancer. The Journal of Urology 2008;179(4):1235‐42. [PUBMED: 18280514]
Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opinion on Investigational Drugs 2007;16(11):1851‐63. [PUBMED: 17970643]
Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, et al. Androgen‐dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock‐in model. Journal of Clinical Investigation 2006;116(10):2663‐72. [PUBMED: 16981011]
